Islet Cell Carcinoma (Insulinoma) Ongoing Global Clinical Trials Analysis and Outlook

June 2018 | 34 pages | ID: I55766CB6D9EN
VPAResearch

Abstracts

Islet Cell Carcinoma (Insulinoma) ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Islet Cell Carcinoma (Insulinoma) disease clinical trials. The research work analyzes the ongoing Islet Cell Carcinoma (Insulinoma) clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Islet Cell Carcinoma (Insulinoma) treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Islet Cell Carcinoma (Insulinoma) clinical trials.

Scope of the Report-

• Ongoing Islet Cell Carcinoma (Insulinoma) clinical trials across regions
• Trial information by Phase and Subjects recruited
• Trial information by status, type, sponsor type
• Drugs used for treatment of Islet Cell Carcinoma (Insulinoma)
• Both observational and interventional trials analyzed
• Leading companies and universities participating in Islet Cell Carcinoma (Insulinoma) clinical trials

Reasons to Buy

• Track competition and design competitive advantages
• Identify right partners to associate with for further research
• Evaluate potential opportunities available in further clinical trials of the disease
• Formulate business development strategies through success rates of clinical trials
• Identify quick markets for recruiting subjects based on trials count by each market

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 KEY FINDINGS, 2018

2.1 Snapshot
2.2 Overview of Islet Cell Carcinoma (Insulinoma) Trials

3 CLINICAL TRIALS TRENDS TO 2022

3.1 Ongoing Islet Cell Carcinoma (Insulinoma) Trials by Phase
3.2 Ongoing Islet Cell Carcinoma (Insulinoma) Trials by Type
3.3 Ongoing Islet Cell Carcinoma (Insulinoma) Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

4.1 Region wise Ongoing Islet Cell Carcinoma (Insulinoma) Trials
4.2 Top 10 Countries conducting Islet Cell Carcinoma (Insulinoma) Trials
4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

5.1 Ongoing Islet Cell Carcinoma (Insulinoma) Trials by Sponsor Type
5.2 Islet Cell Carcinoma (Insulinoma) Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

6.1 Subjects Recruited for Islet Cell Carcinoma (Insulinoma) Trials by year
6.2 Subjects Recruited for Islet Cell Carcinoma (Insulinoma) Trials by Phase
6.3 Subjects Recruited for Islet Cell Carcinoma (Insulinoma) Trials by Trial Type
6.4 Subjects Recruited for Islet Cell Carcinoma (Insulinoma) Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Islet Cell Carcinoma (Insulinoma) Trials- Phase
7.2 Ongoing Islet Cell Carcinoma (Insulinoma) Trials- Phase
7.3 Ongoing Islet Cell Carcinoma (Insulinoma) Trials- Phase
7.4 Ongoing Islet Cell Carcinoma (Insulinoma) Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Islet Cell Carcinoma (Insulinoma)- Clinical Trials by Country
Figure 2: Islet Cell Carcinoma (Insulinoma)- Clinical Trials by Phase of Development, 2018
Figure 3: Islet Cell Carcinoma (Insulinoma)- Clinical Trials by Status, 2018
Figure 4: Islet Cell Carcinoma (Insulinoma)- Clinical Trials by Type, 2018
Figure 5: Islet Cell Carcinoma (Insulinoma)- Clinical Trials Split by Region, 2000-2018
Figure 6: Islet Cell Carcinoma (Insulinoma)- Clinical Trials by Type of Economy, 2018
Figure 7: Islet Cell Carcinoma (Insulinoma)- Enrolment by Phase, 2018
Figure 8: Islet Cell Carcinoma (Insulinoma)- Enrolment by Trial Type, 2018
Figure 9: Islet Cell Carcinoma (Insulinoma)- Enrolment by Recruitment Status, 2018
Figure 10: Islet Cell Carcinoma (Insulinoma)- Clinical Trials by Sponsor Type, 2018
Figure 11: Islet Cell Carcinoma (Insulinoma)- Enrolment by Type of Sponsors
Figure 12: Islet Cell Carcinoma (Insulinoma)- Enrolment by Leading Sponsors

List Of Tables

LIST OF TABLES

Table 1: Islet Cell Carcinoma (Insulinoma)- Clinical Trials by Sponsor Type, 2018
Table 2: Islet Cell Carcinoma (Insulinoma)- Clinical Trials by Economy Type, 2018
Table 3: Islet Cell Carcinoma (Insulinoma)- Clinical Trials by Region, 2018
Table 4: Islet Cell Carcinoma (Insulinoma)- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Islet Cell Carcinoma (Insulinoma)- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Islet Cell Carcinoma (Insulinoma)- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Islet Cell Carcinoma (Insulinoma)- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Islet Cell Carcinoma (Insulinoma)- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Islet Cell Carcinoma (Insulinoma)- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company